KR102896085B1 - 인자 h 강화 항체 및 이의 사용 - Google Patents

인자 h 강화 항체 및 이의 사용

Info

Publication number
KR102896085B1
KR102896085B1 KR1020207023681A KR20207023681A KR102896085B1 KR 102896085 B1 KR102896085 B1 KR 102896085B1 KR 1020207023681 A KR1020207023681 A KR 1020207023681A KR 20207023681 A KR20207023681 A KR 20207023681A KR 102896085 B1 KR102896085 B1 KR 102896085B1
Authority
KR
South Korea
Prior art keywords
sequence
antibody
seq
antigen
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207023681A
Other languages
English (en)
Korean (ko)
Other versions
KR20200110688A (ko
Inventor
타코 윌렘 쿠이퍼스
다이애나 우터스
마리아 클라라 브라우어
리처드 벤자민 파우
Original Assignee
스티흐팅 산퀸 불드포르지닝
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티흐팅 산퀸 불드포르지닝 filed Critical 스티흐팅 산퀸 불드포르지닝
Priority to KR1020257040314A priority Critical patent/KR20250171487A/ko
Publication of KR20200110688A publication Critical patent/KR20200110688A/ko
Application granted granted Critical
Publication of KR102896085B1 publication Critical patent/KR102896085B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207023681A 2018-01-15 2019-01-15 인자 h 강화 항체 및 이의 사용 Active KR102896085B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257040314A KR20250171487A (ko) 2018-01-15 2019-01-15 인자 h 강화 항체 및 이의 사용

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18151726 2018-01-15
EP18151726.9 2018-01-15
PCT/NL2019/050018 WO2019139481A1 (en) 2018-01-15 2019-01-15 Factor h potentiating antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257040314A Division KR20250171487A (ko) 2018-01-15 2019-01-15 인자 h 강화 항체 및 이의 사용

Publications (2)

Publication Number Publication Date
KR20200110688A KR20200110688A (ko) 2020-09-24
KR102896085B1 true KR102896085B1 (ko) 2025-12-08

Family

ID=60972152

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207023681A Active KR102896085B1 (ko) 2018-01-15 2019-01-15 인자 h 강화 항체 및 이의 사용
KR1020257040314A Pending KR20250171487A (ko) 2018-01-15 2019-01-15 인자 h 강화 항체 및 이의 사용

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257040314A Pending KR20250171487A (ko) 2018-01-15 2019-01-15 인자 h 강화 항체 및 이의 사용

Country Status (11)

Country Link
US (2) US11377487B2 (https=)
EP (1) EP3740502A1 (https=)
JP (2) JP7471224B2 (https=)
KR (2) KR102896085B1 (https=)
CN (1) CN111868083B (https=)
AU (1) AU2019206207B2 (https=)
BR (1) BR112020014399A2 (https=)
CA (1) CA3088507A1 (https=)
IL (1) IL276008A (https=)
MX (1) MX2020007555A (https=)
WO (1) WO2019139481A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102896085B1 (ko) * 2018-01-15 2025-12-08 스티흐팅 산퀸 불드포르지닝 인자 h 강화 항체 및 이의 사용
TWI851771B (zh) * 2019-07-17 2024-08-11 美商雙子治療子公司 因子ｈ增強抗體及其用途
CN114560941B (zh) * 2020-11-27 2024-01-16 广东东阳光药业股份有限公司 Cldn18.2的抗体及其应用
US20250121090A1 (en) * 2021-07-30 2025-04-17 R.P. Scherer Technologies, Llc Antibody-Drug Conjugates and Methods of Use Thereof
CN116355860A (zh) * 2021-12-28 2023-06-30 四川远大蜀阳药业有限责任公司 分泌抗h因子抗体的杂交瘤细胞株、抗h因子抗体及其应用
CN116041521B (zh) * 2022-03-21 2023-11-03 南京蓬勃生物科技有限公司 靶向Siglec-15的单克隆抗体及其应用
NL2032398B1 (en) * 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
CN118878671B (zh) * 2024-07-04 2025-09-30 南京农业大学 抗兽疫链球菌SzM蛋白的猪源化单克隆抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508287A (ja) * 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
CN107074939B (zh) * 2014-08-20 2021-09-07 桑昆血液供给基金会 H因子增强抗体及其用途
KR102485788B1 (ko) * 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
KR102896085B1 (ko) * 2018-01-15 2025-12-08 스티흐팅 산퀸 불드포르지닝 인자 h 강화 항체 및 이의 사용
TWI851771B (zh) * 2019-07-17 2024-08-11 美商雙子治療子公司 因子ｈ增強抗體及其用途

Also Published As

Publication number Publication date
US11377487B2 (en) 2022-07-05
JP2023089191A (ja) 2023-06-27
WO2019139481A1 (en) 2019-07-18
KR20200110688A (ko) 2020-09-24
US20220356235A1 (en) 2022-11-10
JP7471224B2 (ja) 2024-04-19
AU2019206207A1 (en) 2020-08-13
JP2021510523A (ja) 2021-04-30
EP3740502A1 (en) 2020-11-25
IL276008A (en) 2020-08-31
CN111868083B (zh) 2025-02-11
CA3088507A1 (en) 2019-07-18
MX2020007555A (es) 2021-01-15
US20210054059A1 (en) 2021-02-25
KR20250171487A (ko) 2025-12-08
CN111868083A (zh) 2020-10-30
BR112020014399A2 (pt) 2020-12-29
AU2019206207B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
KR102896085B1 (ko) 인자 h 강화 항체 및 이의 사용
US20240336676A1 (en) Factor h potentiating antibodies and uses thereof
JP2021178857A (ja) Ｈ因子を強化する抗体及びその用途
AU2020313981B2 (en) Factor H potentiating antibodies and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)